{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T04:52:03Z","timestamp":1791348723593,"version":"4.3.1"},"reference-count":46,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T00:00:00Z","timestamp":1791331200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Computed tomography (CT)-derived vertebral attenuation has been recognized as an indicator of prognosis for patients undergoing tumor removal, liver transplant, or transcatheter arterial chemoembolization (TACE) therapy, but similar research has not been reported in hepatocellular carcinoma (HCC) patients treated with immune checkpoint inhibitors (ICIs). This study aims to explore the prognostic value of CT-derived vertebral attenuation in HCC patients treated with ICIs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective study included HCC patients who received ICI treatment at Wuhan Union Hospital between July 2020 and March 2024. CT-derived vertebral attenuation was assessed by measuring mean Hounsfield unit (HU) values in the center of the first lumbar vertebra (L1) on non-contrast CT scans. Based on the optimal cutoff value derived from X-tile software, patients were classified into the CT-derived L1 attenuation-low group (\u2264100 HU) and the CT-derived L1 attenuation-high group (&amp;gt;100 HU). A comparison of the baseline characteristics of the two groups was made, followed by a propensity score matching (PSM) analysis to balance the variables. The objective response rate (ORR) and disease control rate (DCR) were calculated for both groups, and Kaplan-Meier survival curves and Cox regression models were used to analyze overall survival (OS) and progression-free survival (PFS).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The cohort consisted of 357 patients, divided into the L1 attenuation-low group (n = 112) and the L1 attenuation-high group (n = 245). Among all patients, 30.0% (107\/357) achieved complete or partial response. After PSM analysis, both groups contained 91 patients. The L1 attenuation-low group had shorter OS (hazard ratio [HR], 1.73; 95% confidence interval [CI], 1.15\u20132.60; P\u00a0=\u00a00.008) and PFS (HR, 1.47; 95% CI, 1.04\u20132.08; P\u00a0=\u00a00.030) than the L1 attenuation-high group.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>CT-derived L1 attenuation can stratify survival risk for HCC patients undergoing ICI treatment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1971063","type":"journal-article","created":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T04:49:14Z","timestamp":1791348554000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Low CT-derived vertebral attenuation as a prognostic factor in hepatocellular carcinoma patients treated with immune checkpoint inhibitors"],"prefix":"10.3389","volume":"16","author":[{"given":"Shanshan","family":"Jiang","sequence":"first","affiliation":[{"name":"Department of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","place":["Wuhan, China"]},{"name":"Hubei Provincial Clinical Research Center for Precision Radiology & Interventional Medicine","place":["Wuhan, China"]},{"name":"Hubei Key Laboratory of Molecular Imaging","place":["Wuhan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Ren","sequence":"additional","affiliation":[{"name":"Department of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","place":["Wuhan, China"]},{"name":"Hubei Provincial Clinical Research Center for Precision Radiology & Interventional Medicine","place":["Wuhan, China"]},{"name":"Hubei Key Laboratory of Molecular Imaging","place":["Wuhan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuyang","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","place":["Wuhan, China"]},{"name":"Hubei Provincial Clinical Research Center for Precision Radiology & Interventional Medicine","place":["Wuhan, China"]},{"name":"Hubei Key Laboratory of Molecular Imaging","place":["Wuhan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","place":["Wuhan, China"]},{"name":"Hubei Provincial Clinical Research Center for Precision Radiology & Interventional Medicine","place":["Wuhan, China"]},{"name":"Hubei Key Laboratory of Molecular Imaging","place":["Wuhan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lianwei","family":"Miao","sequence":"additional","affiliation":[{"name":"Department of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","place":["Wuhan, China"]},{"name":"Hubei Provincial Clinical Research Center for Precision Radiology & Interventional Medicine","place":["Wuhan, China"]},{"name":"Hubei Key Laboratory of Molecular Imaging","place":["Wuhan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiwei","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","place":["Wuhan, China"]},{"name":"Hubei Provincial Clinical Research Center for Precision Radiology & Interventional Medicine","place":["Wuhan, China"]},{"name":"Hubei Key Laboratory of Molecular Imaging","place":["Wuhan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guofeng","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Radiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","place":["Wuhan, China"]},{"name":"Hubei Provincial Clinical Research Center for Precision Radiology & Interventional Medicine","place":["Wuhan, China"]},{"name":"Hubei Key Laboratory of Molecular Imaging","place":["Wuhan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,10,7]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.jhep.2018.03.019","article-title":"EASL clinical practice guidelines: Management of hepatocellular carcinoma","volume":"69","author":"Galle","year":"2018","journal-title":"J Hepatol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-21-3275","article-title":"Alpha-fetoprotein as a potential surrogate biomarker for atezolizumab + bevacizumab treatment of hepatocellular carcinoma","volume":"28","author":"Zhu","year":"2022","journal-title":"Clin Cancer Res"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1159\/000481314","article-title":"Efficacy and safety of systemic therapies for advanced hepatocellular carcinoma: A network meta-analysis of phase III trials","volume":"6","author":"Cucchetti","year":"2017","journal-title":"Liver Cancer"},{"key":"B5","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1159\/000449343","article-title":"Hepatocellular carcinoma: Therapeutic guidelines and medical treatment","volume":"6","author":"Kudo","year":"2016","journal-title":"Liver Cancer"},{"key":"B6","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1038\/s41572-020-00240-3","article-title":"Hepatocellular carcinoma","volume":"7","author":"Llovet","year":"2021","journal-title":"Nat Rev Dis Primers"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2019.188314","article-title":"Challenges in liver cancer and possible treatment approaches","volume":"1873","author":"Anwanwan","year":"2020","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1016\/j.cell.2017.05.035","article-title":"Landscape of infiltrating T cells in liver cancer revealed by single-cell sequencing","volume":"169","author":"Zheng","year":"2017","journal-title":"Cell"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N Engl J Med"},{"key":"B10","doi-asserted-by":"publisher","first-page":"8","DOI":"10.21037\/tgh.2019.09.07","article-title":"Hepatobiliary cancers and immunotherapy: Where are we now and where are we heading","volume":"5","author":"Zayac","year":"2020","journal-title":"Transl Gastroenterol Hepatol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1093\/qjmed\/hcac015","article-title":"Bone mineral density, osteopenia and osteoporosis among US adults with cancer","volume":"115","author":"Huang","year":"2022","journal-title":"Qjm"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.21037\/tlcr-23-143","article-title":"Cancer cachexia research: Coming of age","volume":"12","author":"Muqbil","year":"2023","journal-title":"Transl Lung Cancer Res"},{"key":"B13","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1038\/s41598-022-27238-z","article-title":"Association between sarcopenia and clinical outcomes in patients with hepatocellular carcinoma: An updated meta-analysis","volume":"13","author":"Guo","year":"2023","journal-title":"Sci Rep"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(02)08761-5","article-title":"Diagnosis of osteoporosis and assessment of fracture risk","volume":"359","author":"Kanis","year":"2002","journal-title":"Lancet"},{"key":"B15","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1007\/s11657-022-01060-6","article-title":"Prognostic value of preoperative low bone mineral density in patients with digestive cancers: A systematic review and meta-analysis","volume":"17","author":"Watanabe","year":"2022","journal-title":"Arch Osteoporos"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1332303","article-title":"Bone mineral density as an individual prognostic biomarker in NSCLC patients treated with immune checkpoint inhibitors","volume":"15","author":"Lou","year":"2024","journal-title":"Front Immunol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1002\/lt.24458","article-title":"Bone mineral density predicts posttransplant survival among hepatocellular carcinoma liver transplant recipients","volume":"22","author":"Sharma","year":"2016","journal-title":"Liver Transpl"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1007\/s00268-019-05206-5","article-title":"Prognostic impact of osteopenia in patients who underwent living donor liver transplantation for hepatocellular carcinoma","volume":"44","author":"Toshima","year":"2020","journal-title":"World J Surg"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1007\/s00268-018-4861-x","article-title":"Bone mineral density as a risk factor for patients undergoing surgery for hepatocellular carcinoma","volume":"43","author":"Miyachi","year":"2019","journal-title":"World J Surg"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1177\/10732748211038445","article-title":"Body composition changes in hepatocellular carcinoma: Prediction of survival to transcatheter arterial chemoembolization in combination with clinical prognostic factors","volume":"28","author":"Zheng","year":"2021","journal-title":"Cancer Control"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1007\/s00330-022-09069-8","article-title":"Low bone mineral density is a prognostic factor for elderly patients with HCC undergoing TACE: Results from a multicenter study","volume":"33","author":"M\u00fcller","year":"2023","journal-title":"Eur Radiol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-017-4218-6","article-title":"Utilization of bone mineral density testing among breast cancer survivors in British Columbia, Canada","volume":"28","author":"Tseng","year":"2017","journal-title":"Osteoporos Int"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.696183","article-title":"Immunonutritive scoring in patients with hepatocellular carcinoma undergoing transarterial chemoembolization: Prognostic nutritional index or controlling nutritional status score","volume":"11","author":"M\u00fcller","year":"2021","journal-title":"Front Oncol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-158-8-201304160-00003","article-title":"Opportunistic screening for osteoporosis using abdominal computed tomography scans obtained for other indications","volume":"158","author":"Pickhardt","year":"2013","journal-title":"Ann Intern Med"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-04-0713","article-title":"X-tile: A new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization","volume":"10","author":"Camp","year":"2004","journal-title":"Clin Cancer Res"},{"key":"B26","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1055\/s-0030-1247132","article-title":"Modified RECIST (mRECIST) assessment for hepatocellular carcinoma","volume":"30","author":"Lencioni","year":"2010","journal-title":"Semin Liver Dis"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1148\/rg.2021200056","article-title":"Opportunistic screening at abdominal CT: Use of automated body composition biomarkers for added cardiometabolic value","volume":"41","author":"Pickhardt","year":"2021","journal-title":"Radiographics"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3340\/jkns.2013.54.5.384","article-title":"Correlation between bone mineral density measured by dual-energy X-ray absorptiometry and Hounsfield units measured by diagnostic CT in lumbar spine","volume":"54","author":"Lee","year":"2013","journal-title":"J Korean Neurosurg Soc"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1002\/jbmr.428","article-title":"Simultaneous screening for osteoporosis at CT colonography: Bone mineral density assessment using MDCT attenuation techniques compared with the DXA reference standard","volume":"26","author":"Pickhardt","year":"2011","journal-title":"J Bone Miner Res"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1148\/radiol.2019181648","article-title":"Opportunistic osteoporosis screening at routine abdominal and thoracic CT: Normative L1 trabecular attenuation values in more than 20 000 adults","volume":"291","author":"Jang","year":"2019","journal-title":"Radiology"},{"key":"B31","doi-asserted-by":"publisher","first-page":"29","DOI":"10.3390\/diagnostics16010029","article-title":"Opportunistic bone health assessment using contrast-enhanced abdominal CT: A DXA-referenced analysis in liver transplant recipients","volume":"16","author":"Dag","year":"2025","journal-title":"Diagnostics (Basel)"},{"key":"B32","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.3390\/diagnostics16091340","article-title":"Longitudinal CT-based assessment of muscle and bone changes after liver transplantation in hepatitis B patients with and without hepatocellular carcinoma","volume":"16","author":"Dag","year":"2026","journal-title":"Diagnostics (Basel)"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1200\/jco.23.00225","article-title":"Irreconcilable differences: The divorce between response rates, progression-free survival, and overall survival","volume":"41","author":"Merino","year":"2023","journal-title":"J Clin Oncol"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1507643","article-title":"Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer","volume":"373","author":"Borghaei","year":"2015","journal-title":"N Engl J Med"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(18)32409-7","article-title":"Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): A randomised, open-label, controlled, phase 3 trial","volume":"393","author":"Mok","year":"2019","journal-title":"Lancet"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-11-255026","article-title":"Cross talk between the bone and immune systems: Osteoclasts function as antigen-presenting cells and activate CD4+ and CD8+ T cells","volume":"116","author":"Li","year":"2010","journal-title":"Blood"},{"key":"B37","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1038\/nri2062","article-title":"Osteoimmunology: Shared mechanisms and crosstalk between the immune and bone systems","volume":"7","author":"Takayanagi","year":"2007","journal-title":"Nat Rev Immunol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1038\/nature04524","article-title":"Regulation of cancer cell migration and bone metastasis by RANKL","volume":"440","author":"Jones","year":"2006","journal-title":"Nature"},{"key":"B39","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.critrevonc.2018.10.011","article-title":"RANK\/RANKL signaling inhibition may improve the effectiveness of checkpoint blockade in cancer treatment","volume":"133","author":"van Dam","year":"2019","journal-title":"Crit Rev Oncol Hematol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1002\/jcsm.13563","article-title":"Co-morbid sarcopenia and low bone mineral density in young paediatric cancer survivors","volume":"15","author":"Marmol-Perez","year":"2024","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1007\/s00198-013-2346-1","article-title":"The effect of physical exercise on bone density in middle-aged and older men: A systematic review","volume":"24","author":"Bolam","year":"2013","journal-title":"Osteoporos Int"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.2147\/cia.s23927","article-title":"A review of minodronic acid hydrate for the treatment of osteoporosis","volume":"8","author":"Tanishima","year":"2013","journal-title":"Clin Interv Aging"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1111\/liv.14223","article-title":"Biology and significance of alpha-fetoprotein in hepatocellular carcinoma","volume":"39","author":"Galle","year":"2019","journal-title":"Liver Int"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.2147\/JHC.S285735","article-title":"Current strategies to identify patients that will benefit from TACE treatment and future directions a practical step-by-step guide","volume":"8","author":"M\u00fcller","year":"2021","journal-title":"J Hepatocell Carcinoma"},{"key":"B45","doi-asserted-by":"publisher","first-page":"2050640620972611","DOI":"10.1177\/2050640620972611","article-title":"High pre-treatment static and dynamic alpha-fetoprotein values predict reduced overall survival in hepatocellular carcinoma","volume":"9","author":"Czauderna","year":"2020","journal-title":"United Eur Gastroenterol J"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29086","article-title":"AASLD guidelines for the treatment of hepatocellular carcinoma","volume":"67","author":"Heimbach","year":"2018","journal-title":"Hepatology"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1971063\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T04:49:16Z","timestamp":1791348556000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1971063\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,7]]},"references-count":46,"alternative-id":["10.3389\/fonc.2026.1971063"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1971063","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,7]]},"article-number":"1971063"}}